Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Moderna's Q4 2025 Earnings: What to Expect

Cambridge, Massachusetts-based Moderna, Inc. (MRNA), a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases. The company is valued at $15.9 billion by market cap. The pharmaceutical and biotechnology company is expected to announce its fiscal fourth-quarter earnings for 2025 in the near term. 

Ahead of the event, analysts expect MRNA to report a loss of $2.79 per share on a diluted basis, down 11.6% from $2.50 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s bottom-line estimates in its last four quarterly reports. 

Fundamentals

See More
  • Market Capitalization, $K 15,379,291
  • Shares Outstanding, K 390,734
  • Annual Sales, $ 3,236 M
  • Annual Income, $ -3,561 M
  • EBIT $ -3,463 M
  • EBITDA $ -3,369 M
  • 60-Month Beta 1.17
  • Price/Sales 7.37
  • Price/Cash Flow N/A
  • Price/Book 1.70

Options Overview Details

View History
  • Implied Volatility 68.51% (+2.45%)
  • Historical Volatility 75.11%
  • IV Percentile 45%
  • IV Rank 28.67%
  • IV High 104.55% on 04/08/25
  • IV Low 54.03% on 08/06/25
  • Expected Move (DTE 6) 2.35 (5.61%)
  • Put/Call Vol Ratio 0.32
  • Today's Volume 97,289
  • Volume Avg (30-Day) 83,804
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 1,139,166
  • Open Int (30-Day) 1,047,237
  • Expected Range 39.48 to 44.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.81
  • Number of Estimates 9
  • High Estimate -2.50
  • Low Estimate -3.15
  • Prior Year -2.50
  • Growth Rate Est. (year over year) -12.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.06 +43.94%
on 12/31/25
42.39 -1.32%
on 01/16/26
+11.94 (+39.95%)
since 12/16/25
3-Month
22.28 +87.75%
on 11/21/25
42.39 -1.32%
on 01/16/26
+14.69 (+54.13%)
since 10/16/25
52-Week
22.28 +87.75%
on 11/21/25
45.40 -7.86%
on 01/24/25
+8.07 (+23.90%)
since 01/16/25

Most Recent Stories

More News
Moderna's Q4 2025 Earnings: What to Expect

Moderna will release its fourth-quarter earnings soon, and analysts anticipate a low double-digit loss decline.

XLV : 155.74 (-0.78%)
$SPX : 6,940.01 (-0.06%)
MRNA : 41.83 (+6.28%)
Wall Street slumps as bank and tech stocks fall

Losses for several banks and Big Tech stocks pulled U.S. indexes lower, even though the majority of stocks on Wall Street rose

NVDA : 186.23 (-0.44%)
AAPL : 255.53 (-1.04%)
C : 118.04 (+0.49%)
AVGO : 351.71 (+2.53%)
BAC : 52.97 (+0.72%)
CVX : 166.26 (+0.06%)
COP : 98.19 (-0.75%)
JPM : 312.47 (+1.04%)
$SPX : 6,940.01 (-0.06%)
$IUXX : 25,529.26 (-0.07%)
WFC : 88.38 (-0.65%)
XOM : 129.89 (+0.59%)
Stock Index Futures Slip With Focus on U.S. Retail Sales and PPI Data, More Big Bank Earnings on Tap

March S&P 500 E-Mini futures (ESH26) are down -0.44%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.66% this morning as investors trim risk ahead of a slew of U.S. economic data, including the...

NFLX : 88.00 (-0.06%)
C : 118.04 (+0.49%)
BAC : 52.97 (+0.72%)
SMCI : 32.64 (+10.94%)
RIVN : 16.67 (-2.29%)
ESH26 : 6,976.75s (-0.07%)
MA : 539.49 (-0.58%)
WFC : 88.38 (-0.65%)
FTNT : 75.38 (-1.23%)
V : 328.30 (+0.17%)
NQH26 : 25,689.00s (-0.07%)
ADBE : 296.12 (-2.62%)
Wall Street pulls back from its records as JPMorgan Chase and Delta kick off earnings season

Wall Street pulled back from its records following a mixed start to the latest profit reporting season for big U.S. companies

SYF : 80.19 (+3.20%)
GOOGL : 330.00 (-0.84%)
AAPL : 255.53 (-1.04%)
$SPX : 6,940.01 (-0.06%)
JPM : 312.47 (+1.04%)
CAH : 212.45 (-0.47%)
$IUXX : 25,529.26 (-0.07%)
AXP : 364.79 (+2.08%)
$DOWI : 49,359.33 (-0.17%)
CME : 279.50 (+2.53%)
CMG : 39.96 (-0.99%)
MRNA : 41.83 (+6.28%)
Stocks Fall on Weakness in Software and Credit Card Companies

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.19%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.80%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.18%. March E-mini...

GOOGL : 330.00 (-0.84%)
INTU : 545.29 (-1.68%)
JPM : 312.47 (+1.04%)
$IUXX : 25,529.26 (-0.07%)
ZNH26 : 111-240s (-0.42%)
MSFT : 459.86 (+0.70%)
ESH26 : 6,976.75s (-0.07%)
MA : 539.49 (-0.58%)
V : 328.30 (+0.17%)
AMD : 231.83 (+1.72%)
$DOWI : 49,359.33 (-0.17%)
CMG : 39.96 (-0.99%)
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings Call

MRNA : 41.83 (+6.28%)
3 Unprofitable Stocks We Keep Off Our Radar

3 Unprofitable Stocks We Keep Off Our Radar

MODG : 14.68 (+0.55%)
HAS : 86.20 (-0.79%)
MRNA : 41.83 (+6.28%)
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010

MRNA : 41.83 (+6.28%)
1 Mooning Stock to Own for Decades and 2 We Find Risky

1 Mooning Stock to Own for Decades and 2 We Find Risky

NXDR : 1.9100 (-2.55%)
MRNA : 41.83 (+6.28%)
DASH : 205.32 (-2.28%)
Why Is Moderna (MRNA) Stock Rocketing Higher Today

Why Is Moderna (MRNA) Stock Rocketing Higher Today

MRNA : 41.83 (+6.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 44.47
2nd Resistance Point 43.43
1st Resistance Point 42.63
Last Price 41.83
1st Support Level 40.79
2nd Support Level 39.75
3rd Support Level 38.95

See More

52-Week High 45.40
Last Price 41.83
Fibonacci 61.8% 36.57
Fibonacci 50% 33.84
Fibonacci 38.2% 31.11
52-Week Low 22.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar